Stockreport

Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension

CONATUS PHARMACEUTICALS INC  (CNAT) 
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.conatuspharma.com/investor-relations
PDF SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral present [Read more]